Search

everythinglearnresearchcommunity

for

Search:↓

Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.

CCCA involves immune response and metabolism issues, suggesting new treatment options.

The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.

A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.

Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.

The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.

Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.

There is no standardized treatment for hidradenitis suppurativa, and individualized plans are needed.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

Adalimumab may cause severe hair loss in some patients.

Swiss experts recommend specific guidelines for diagnosing and treating hidradenitis suppurativa to improve patient care.

The guideline recommends using specific drugs and surgery together for treating hidradenitis suppurativa effectively.

Hidradenitis suppurativa might be a type of autoinflammatory skin disease.

A woman developed hair loss after starting a treatment with adalimumab, suggesting this medication might cause hair loss.

A woman with severe hair loss was successfully treated with the drug adalimumab.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

Some drugs used to treat inflammation may cause hair loss.

Adalimumab improved folliculitis decalvans in most patients.

Hydroxychloroquine showed some potential, but overall, the three drugs had limited success in treating lupus in dogs.

The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Adalimumab was safe but mostly ineffective for severe alopecia areata.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.